Neoadjuvant immunochemotherapy for resectable esophageal cancer: A study on efficacy and safety

Neoadjuvant immunochemotherapy for resectable esophageal cancer: A study on efficacy and safety

The combination of immunosuppressants and chemotherapy has reshaped the treatment landscape for esophageal cancer (EC). This study aimed to evaluate the effectiveness and safety of a neoadjuvant immunochemotherapy (nICT) regimen in patients with resectable EC. A total of 99 eligible patients were i...

Full description

Saved in:

Bibliographic Details
Main Authors:	Xiaomin Wang, Bingxu Li, Zhiyong Zheng, Weijie Wang
Format:	Article
Language:	English
Published:	Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina 2025-04-01
Series:	Biomolecules & Biomedicine
Subjects:	Immunotherapy chemotherapy neoadjuvant therapy esophageal cancer EC neoadjuvant immunochemotherapy
Online Access:	http://www.bjbms.org/ojs/index.php/bjbms/article/view/11806
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma: a clinical retrospective study
by: Jiazhen Chen, et al.
Published: (2025-08-01)

Adjuvant immunotherapy after neoadjuvant immunochemotherapy and esophagectomy for esophageal squamous cell carcinoma: a real-world study
by: Jifeng Feng, et al.
Published: (2024-12-01)

Clinical efficacy of different neoadjuvant therapies for resectable esophageal squamous cell carcinoma
by: Xiaoyang Wang, et al.
Published: (2025-06-01)

Pretreatment immune-inflammatory prognostic score in predicting clinical outcomes in esophageal squamous cell carcinoma receiving neoadjuvant immunochemotherapy
by: Qiang Zhao, et al.
Published: (2025-08-01)

Prognostic analysis of esophageal cancer patients after neoadjuvant therapy
by: Jing Dong, et al.
Published: (2025-02-01)

Neoadjuvant sintilimab and chemotherapy for resectable esophageal squamous cell carcinoma: a phase II clinical trial
by: Jincheng Guo, et al.
Published: (2025-04-01)

Effectiveness and Safety of Neoadjuvant Immunochemotherapy with and without Surgery in Patients with Resectable Esophageal Squamous Cell Carcinoma: A Retrospective Cohort Study
by: Liao X, et al.
Published: (2025-06-01)

Longitudinal immune monitoring of patients with resectable esophageal adenocarcinoma treated with Neoadjuvant PD-L1 checkpoint inhibition
by: Tom van den Ende, et al.
Published: (2023-12-01)

Nomogram-based risk stratification to analyze the value of receiving postoperative adjuvant therapy after neoadjuvant immunochemotherapy for patients with locally advanced esophageal squamous carcinoma
by: Qiuying An, et al.
Published: (2025-07-01)

The efficacy and safety of adjuvant immunotherapy after neoadjuvant immunotherapy combined with chemotherapy in locally advanced resectable esophageal squamous cell carcinoma: a real−world study
by: Xue Wu, et al.
Published: (2025-05-01)

Neoadjuvant immunochemotherapy versus neoadjuvant immunoradiotherapy in locally advanced oral squamous cell carcinoma
by: Gaofeng Ding, et al.
Published: (2025-05-01)

A Meta‐Analysis of Efficacy and Safety of Neoadjuvant Immunotherapy Plus Chemotherapy for Resectable Non‐Small Cell Lung Cancer
by: Xinru Sun, et al.
Published: (2024-10-01)

Recent Advances and Hot Spots of Neoadjuvant Immunotherapy Combined with Chemotherapy for Esophageal Carcinoma
by: Huilai LYU, et al.
Published: (2024-12-01)

Neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma: a retrospective study with 2-year survival analysis
by: Chong-Rui Li, et al.
Published: (2025-07-01)

Clinical efficacy and biomarkers of neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma
by: Siyou Deng, et al.
Published: (2025-06-01)

Neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma in real-world practice: an analysis of the clinical outcomes and long-term survival, and the feasibility of using major pathological response as a surrogate endpoint
by: Jiacong Liu, et al.
Published: (2025-04-01)

Oncologic outcomes following neoadjuvant immunochemotherapy in locally advanced oral squamous cell carcinoma
by: Gang Li, et al.
Published: (2025-05-01)

Impact of Interval to Esophagectomy After Neoadjuvant Immunochemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter Retrospective Cohort Analysis
by: Hui Xu, et al.
Published: (2025-03-01)

Development and validation of a postoperative risk model for esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy
by: Hai Zhang, et al.
Published: (2025-08-01)

Neoadjuvant chemoimmunotherapy versus neoadjuvant chemoradiotherapy in patients with borderline resectable esophageal squamous cell carcinoma
by: Jun-Peng Lin, et al.
Published: (2025-08-01)

Effects of perioperative treatment of resectable adenocarcinoma of esophagogastric junction by immunotherapy (Adebrelimab) combined with chemotherapy (XELOX): protocol for a single-center, open-labeled study (AEGIS trial, neoadjuvant immunochemotherapy)
by: Yingyi Li, et al.
Published: (2025-02-01)

Predicting pathological response of resectable esophageal squamous cell carcinoma to neoadjuvant anti-PD-1 with chemotherapy using serum inflammation indexes
by: Peng Song, et al.
Published: (2025-07-01)

CT-based radiomics for prediction of response to neoadjuvant immunochemotherapy in patients with esophageal carcinoma
by: Peng Zhao, et al.
Published: (2025-05-01)

Real-world safety and efficacy of neoadjuvant docetaxel, cisplatin, and 5-fluorouracil therapy for locally advanced esophageal squamous cell carcinoma
by: Mikako Tamba, et al.
Published: (2025-04-01)

Prolonged time interval from neoadjuvant immunotherapy combined with chemotherapy to surgery is related to unimproved pathological response and poor survival prognosis for esophageal squamous cell carcinoma
by: Guanzhi Ye, et al.
Published: (2025-04-01)

Neoadjuvant immunochemotherapy versus chemotherapy for elderly patients with IB–IIIB non-small-cell lung cancer in real-world practice
by: Yongfeng Shuai, et al.
Published: (2025-07-01)

Case Report: Pathological complete response achieved with neoadjuvant immunochemotherapy in synchronous multiple gastric adenocarcinoma
by: Ya-hui Sun, et al.
Published: (2025-07-01)

Indications for neoadjuvant radiation in esophageal adenocarcinoma: Times are changingCentral Message
by: Stephanie G. Worrell, MD, FACS
Published: (2024-06-01)

In‐Depth Analysis of the Necessity and Optimization Strategies for Adjuvant Radiotherapy Following Neoadjuvant Immunotherapy in the New Era of Esophageal Cancer Treatment
by: Guohui Liu, et al.
Published: (2025-06-01)

Effect of immune infiltration intensity on the efficacy of neoadjuvant immunotherapy for esophageal cancer
by: Yong Zhang, et al.
Published: (2025-06-01)

Analysis of Efficacy and Safety of Neoadjuvant Immunochemotherapy in Patients with Stage IB-IIIB Non-small Cell Lung Cancer
by: Zihao LI, et al.
Published: (2025-06-01)

Analysis of the safety and efficacy of PD-1/PD-L1 inhibitors combined with chemotherapy in the treatment of locally advanced resectable esophageal squamous cell carcinoma: a systematic review and meta-analysis based on four randomized controlled trials
by: Tao Luo, et al.
Published: (2025-08-01)

The efficacy of neoadjuvant immunotherapy and lymphocyte subset predictors in locally advanced esophageal squamous cell carcinoma: A retrospective study
by: Ruotong Wang, et al.
Published: (2024-09-01)

Tertiary lymphoid structures correlate with the therapeutic efficacy and prognosis of resectable esophageal squamous cell carcinoma undergoing neoadjuvant chemoradiotherapy plus immunotherapy
by: Ke Zhai, et al.
Published: (2025-08-01)

To compare and determine the diagnostic accuracy of [18F]-fluorodeoxyglucose positron emission tomography scan in predicting pathological response in operated carcinoma esophagus patients after initial neoadjuvant chemoradiation and neoadjuvant chemotherapy
by: Neelam Sharma, et al.
Published: (2018-04-01)

Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab versus neoadjuvant chemotherapy plus tislelizumab for locally advanced esophageal squamous cell cancer: a real-world retrospective study
by: Qi Zhao, et al.
Published: (2025-08-01)

EFFICACY OF COMBINED MODALITY TREATMENT INCLUDING NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH ESOPHAGEAL CANCER
by: Yu. V. Rudyk, et al.
Published: (2016-02-01)

Nodal Downstaging of Esophageal Cancer After Neoadjuvant Therapy: A Cohort Study and Meta‐Analysis
by: Feng Su, et al.
Published: (2025-02-01)

Prognostic factors in locally advanced oesophageal squamous cell carcinoma: a clinical and radiomic analysis of neoadjuvant immunochemotherapy before surgery
by: Yan Zhu, et al.
Published: (2025-03-01)

Comparative efficacy and safety of first-line neoadjuvant therapy for early-stage non-small cell lung cancer based on immune checkpoint inhibitor therapy: a systematic review and network meta-analysis
by: Linfeng Wang, et al.
Published: (2025-01-01)